Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective inhibition of receptor activator of NF-κB ligand (RANKL) in hematopoietic cells improves outcome after experimental myocardial infarction.
Slavic S, Andrukhova O, Ford K, Handschuh S, Latic N, Reichart U, Sasgary S, Bergow C, Hofbauer LC, Kostenuik PJ, Erben RG. Slavic S, et al. Among authors: kostenuik pj. J Mol Med (Berl). 2018 Jun;96(6):559-573. doi: 10.1007/s00109-018-1641-x. Epub 2018 May 8. J Mol Med (Berl). 2018. PMID: 29736604 Free PMC article.
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S, Warmington K, Adamu S, Asuncion F, Geng Z, Grisanti M, Tan HL, Capparelli C, Starnes C, Weimann B, Dunstan CR, Kostenuik PJ. Morony S, et al. Among authors: kostenuik pj. Endocrinology. 2005 Aug;146(8):3235-43. doi: 10.1210/en.2004-1583. Epub 2005 Apr 21. Endocrinology. 2005. PMID: 15845617
The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D. Padagas J, et al. Calcif Tissue Int. 2006 Jan;78(1):35-44. doi: 10.1007/s00223-005-0161-1. Epub 2005 Dec 5. Calcif Tissue Int. 2006. PMID: 16362459
RANKL inhibition: from mice to men (and women).
Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ. Stolina M, et al. Among authors: kostenuik pj. Adv Exp Med Biol. 2007;602:143-50. doi: 10.1007/978-0-387-72009-8_18. Adv Exp Med Biol. 2007. PMID: 17966399 Review.
RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats.
Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ. Ominsky MS, et al. Among authors: kostenuik pj. J Bone Miner Res. 2008 May;23(5):672-82. doi: 10.1359/jbmr.080109. J Bone Miner Res. 2008. PMID: 18433301 Free article.
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells.
Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Schüler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG. Streicher C, et al. Among authors: kostenuik pj. Sci Rep. 2017 Jul 25;7(1):6460. doi: 10.1038/s41598-017-06614-0. Sci Rep. 2017. PMID: 28744019 Free PMC article.
121 results